Principal
WLM BioPharma Consulting, LLC.
2021 – Present year
Hollywood, FL, United States
Provide comprehensive consulting services related to market access by launching and growing biotechnology companies focused on high unmet needs in rare and specialty diseases.
Vice President, Market Access
Enzyvant
2021 – Present year
Cambridge, Massachusetts, United States
Led US Market Access organization consisting of Payer Strategies, Value and Health Economics and Outcomes Research, Patient Support Services, Distribution and Pricing.
– Launched first in class, single dose regenerative medicine RETHYMIC, which became the only FDA approved treatment for Congenital Athymia.
Senior Vice President, Market Access (Acquired by Horizon Therapeutics 3/15/21)
Viela Bio
2019 – 2021
Gaithersburg, Maryland, United States
Accountable for payer strategies, government services and rebates, distribution strategy, reimbursement, patient support services and access programs, and pricing across an ultra-orphan/orphan product portfolio.
* Executed the launch of Uplizna (FDA approved 6/11/20) for neuromyelitis optica spectrum disorder during COVID-19, successfully navigated emerging trends, payer mix shifts, and increased patient assistance needs.
* Led the Healthcare Common Procedure Coding System (HCPCS) submission team and received J-code within five months post approval.
* Designed and developed a flexible and scalable channel strategy and distribution model, including third party logistics, specialty distribution, and specialty pharmacy to maximize health care providers and patient convenience, aligned with budgetary goals.
* Spearheaded and collaborated with Medical Affairs, Clinical, and Marketing on value proposition and message creation, health economics and outcomes research (HEOR) for the Academy of Managed Care Pharmacists (AMCP) and Global Value dossiers for payers.
* Incorporated patient input on journey to build patient support services including HUB model design, co-pay assistance, and patient access programs for ease of access and satisfaction.
* Directed all government affairs and services management, including mandatory rebates, price reporting and coverage submissions for Medicare, Medicaid, Veteran’s Administration, Federal Supply Schedule, collaborating with Finance for compliant on time reporting.
* Promoted from Vice President to Senior Vice President
Senior Director, U.S. Market Access
Amicus Therapeutics
2015 – 2019
Cranbury, New Jersey, United States
Spearheaded all Commercial activities prior to launch as well as U.S. Market Access, including payer strategies, account management, distribution strategy, reimbursement, patient support services, patient access programs, and pricing across Amicus’ ultra-orphan product portfolio.
* Designed and developed a flexible and scalable channel strategy and distribution model, including third party logistics and specialty pharmacies to provide rapid access for patients.
* Developed commercial and government payer strategies and objectives to ensure favorable payer coverage. Created an innovative model to maximize strategic alliances for rapid payer acceptance, including a value proposition and messaging that minimized payer restrictions.
* Implemented and optimized patient support services, including HUB model design and created a hybrid model to provide superior patient access.
* Spearheaded U.S. portfolio pricing evaluation and global insights to successfully minimize payer utilization management.
NPS Pharmaceuticals
Senior Director, Market Access and Key Accounts (Acquired by Shire 2/20/15)
2014 – 2015
Bedminster, New Jersey, United States
Led and hired entire Market Access team.
* Launched two first in class ultra-orphan/orphan products, Gattex, Glucagon-Like peptide-2 (GLP-2) and Natpara (parathyroid hormone).
* Ensured payer readiness for Natpara (parathyroid hormone) launch, including disease awareness and burden of illness.
* Coordinated payer education on Risk Evaluation and Mitigation Strategy (REMS) program for Gattex, which included health care professional training and a medication guide.
Key Account Director
2012 – 2014
Bedminster, New Jersey, United States
* Launched of Gattex (ultra orphan), first in class GLP-2.
* Oversaw commercial, government, Medicaid, Medicare Part D accounts as well as PBMs and SPs.
* Partnered with multidisciplinary team to amend restrictive payer policies.
Corporate Account Director
Dyax Corp.
2011 – 2012
Burlington, Massachusetts, United States
Director, Corporate Accounts, Central Region
Enabled product access for Kalbitor and maintained favorable reimbursement status within commercial, government payers as well as specialty pharmacies and integrated health systems in 13 states.
Director, Managed Markets, (Acquired by Sanofi 4/11)
Sanofi Genzyme
2002 – 2011
Cambridge, Massachusetts, United States
Director, Managed Markets, Personalized Genetic Health Division (2003 – 2011)
* Managed a highly profitable integrated team with responsibility for 13 states
Clinical Science Associate, Ohio & Indiana (2002 – 2003)
Senior Clinical Oncology Specialist
Genentech
1991 – 2002
South San Francisco, California, United States
Senior Clinical Oncology Specialist (1999 – 2002)
* Successfully launched Rituxan and Herceptin.
Senior Clinical Account Specialist (1991 – 1999)